Breast conserving treatment for ductal carcinoma in situ in the elderly: can radiation therapy be avoided? Our experience

Int J Surg. 2014:12 Suppl 2:S47-S49. doi: 10.1016/j.ijsu.2014.08.382. Epub 2014 Aug 26.

Abstract

Introduction: Ductal Carcinoma In Situ (DCIS) is a heterogeneous, pre-malignant disease accounting for 15-20% of all new breast cancers. If appropriately managed, DCIS has a small chance of impacting on patient life expectancy. Despite the possibility of a further recurrence or of a development in an invasive form, we are unable to select treatment of choice especially in the elderly. In particularly we risk an overtreatment of women at low risk of progression to invasive breast cancer. The aim of this study was to retrospectively evaluate the outcome of elderly patients affected by DCIS not undergoing Radiation Therapy (RT) after Breast Conserving Surgery (BCS).

Material and methods: We reviewed our prospectively-maintained database from 1998 to 2013, selecting all women over 65 years old diagnosed with DCIS who did not receive RT for personal choice. We considered two groups, according to the risk of local recurrence (Low Risk (Group 1) vs. High Risk (Group 2)).

Results: We identified 44 cases of DCIS treated with surgery alone or with surgery followed by adjuvant tamoxifen. 24 patients presented low risk of local recurrence (Group 1) and 20 had characteristics associated to high risk of local recurrence (Group 2). At a median follow-up of 66.3 months, no local recurrences have been described in group 1. No patients presented distant metastases, while 4 patients died for other causes. At a median follow-up of 72 months we observed 5 local recurrences in the second group (p < 0.05).

Conclusion: Our results suggest that radiation therapy can be safely avoided in a selected group of elderly patients affected by DCIS.

Keywords: Breast cancer; Breast conserving treatment; Ductal carcinoma in situ; Radiation therapy.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Breast Neoplasms / surgery*
  • Carcinoma, Intraductal, Noninfiltrating / surgery*
  • Chemotherapy, Adjuvant
  • Female
  • Humans
  • Mastectomy, Segmental*
  • Neoplasm Recurrence, Local / prevention & control*
  • Radiotherapy, Adjuvant
  • Retrospective Studies
  • Risk
  • Tamoxifen / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Hormonal
  • Tamoxifen